Equities research analysts expect Intersect ENT, Inc. (NASDAQ:XENT) to post earnings per share of ($0.20) for the current quarter, according to Zacks. Five analysts have made estimates for Intersect ENT’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.10). Intersect ENT reported earnings per share of ($0.22) in the same quarter last year, which indicates a positive year over year growth rate of 9.1%. The company is expected to issue its next quarterly earnings results on Wednesday, November 1st.

On average, analysts expect that Intersect ENT will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.48). For the next financial year, analysts anticipate that the business will report earnings of ($0.38) per share, with EPS estimates ranging from ($0.59) to ($0.24). Zacks’ EPS averages are an average based on a survey of research analysts that cover Intersect ENT.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.57% and a negative net margin of 22.94%. The firm had revenue of $24 million during the quarter, compared to analyst estimates of $22.62 million. During the same period last year, the company posted ($0.21) EPS. The business’s quarterly revenue was up 24.4% compared to the same quarter last year.

A number of research firms recently issued reports on XENT. TheStreet upgraded Intersect ENT from a “d” rating to a “c-” rating in a report on Tuesday, August 1st. Canaccord Genuity reiterated a “buy” rating and set a $32.00 price objective on shares of Intersect ENT in a report on Wednesday, August 2nd. Northland Securities reiterated a “hold” rating and set a $25.00 price objective on shares of Intersect ENT in a report on Wednesday, August 2nd. BidaskClub downgraded Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Deutsche Bank AG set a $31.00 price objective on Intersect ENT and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $23.13.

Shares of Intersect ENT (NASDAQ:XENT) traded up 3.04% during midday trading on Monday, reaching $30.55. The company’s stock had a trading volume of 368,733 shares. The stock has a 50-day moving average of $27.55 and a 200 day moving average of $20.21. The company’s market cap is $884.42 million. Intersect ENT has a 12 month low of $7.65 and a 12 month high of $30.65.

In related news, CFO Jeryl L. Hilleman sold 12,835 shares of the stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $27.18, for a total transaction of $348,855.30. Following the completion of the transaction, the chief financial officer now directly owns 27,835 shares of the company’s stock, valued at $756,555.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $22.98, for a total value of $459,600.00. Following the transaction, the insider now directly owns 600,868 shares of the company’s stock, valued at $13,807,946.64. The disclosure for this sale can be found here. Insiders have sold 105,335 shares of company stock valued at $2,721,580 over the last three months. Insiders own 13.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. American International Group Inc. boosted its position in shares of Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after buying an additional 1,037 shares during the period. Blair William & Co. IL boosted its position in shares of Intersect ENT by 32.4% in the first quarter. Blair William & Co. IL now owns 39,900 shares of the medical equipment provider’s stock valued at $543,000 after buying an additional 9,756 shares during the period. TFS Capital LLC boosted its position in shares of Intersect ENT by 74.9% in the first quarter. TFS Capital LLC now owns 51,426 shares of the medical equipment provider’s stock valued at $882,000 after buying an additional 22,024 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Intersect ENT by 10.8% in the first quarter. Bank of New York Mellon Corp now owns 150,540 shares of the medical equipment provider’s stock valued at $2,582,000 after buying an additional 14,659 shares during the period. Finally, C WorldWide Group Holding A S boosted its position in shares of Intersect ENT by 10.0% in the first quarter. C WorldWide Group Holding A S now owns 181,550 shares of the medical equipment provider’s stock valued at $3,114,000 after buying an additional 16,550 shares during the period. 76.11% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/0-20-earnings-per-share-expected-for-intersect-ent-inc-nasdaqxent-this-quarter.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.